

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Doseology Sciences Inc. (the “Company”)
406 - 460 Doyle Avenue
Kelowna, BC V1Y 0C2

Item 2: Date of Material Change

April 18, 2023.

Item 3: News Release

A news release was issued and disseminated May 5, 2023 and filed on SEDAR at www.sedar.com.

Item 4: Summary of Material Changes

The Company announced the changes to its directors and officers. See item 5 for further details.

Item 5: Full Description of Material Change

The Company announced the appointment of Shawn Balaghi as a director of the Company, and Lindsay Hamelin as Corporate Secretary of the Company.

Shawn brings over 20 years of experience in the capital markets industry globally, holding key roles in finance, corporate development, and strategic planning. Previously, he has served as the CEO and CFO for several publicly listed companies and has worked closely with some of the largest independent auditing firms in Canada and the US. Shawn has raised over \$300 Million in funding for several start-ups and has led them to public listings in Canada, the US, and Germany. Shawn has been the President, Director & Co-Founder of RED Bioscience since July 2020, the President of Thrive California Industries Inc. since March 2018, and performing investor relations services for Northern Lights Resources Inc. since December 2020.

Lindsay has 17 years experience as a self-employed consultant and working in leading Canadian law firms. During her career, she has focused on securities and corporate finance and assists with managing and orchestrating public company requirements with a focus on the CSE, TSXV and TSX stock exchanges, as well as listings on the OTC Markets.

The Company also announced that Dustin Merritt has resigned as the Corporate Secretary of the Company and wishes him well in his future endeavors.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

Noe applicable.

Item 8: Executive Officer

For further information, please contact:

Pratik Patel, Interim CEO

Investor Relations: investor@doseology.com

General Inquiries: hello@doseology.com

Telephone: 236-349-0064

Item 9: Date of Report

May 5, 2023.